June 3, 2024

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

New England Journal of Medicine, Ahead of Print.

June 3, 2024

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma – nejm.org

June 3, 2024

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial – Nature.com

June 1, 2024

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma – nejm.org

May 20, 2024

Multiple Myeloma in Central Europe and the Baltics: Supporting early and equitable access to care to improve patient outcomes – Economist Impact